Covered recipient · General Payments record
ROBERT L SMITH
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$1,147.68
- Reported across 60 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $301.23 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Lilly USA, LLC | $77.77 | 4 |
| PFIZER INC. | $48.55 | 2 |
| Novo Nordisk AS | $37.17 | 2 |
| Amgen Inc. | $32.06 | 2 |
| Acerta Pharma LLC | $28.84 | 2 |
| ABBVIE INC. | $26.89 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $18.71 | 1 |
| Esperion Therapeutics, Inc. | $16.35 | 1 |
| Astellas Pharma US Inc | $14.89 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| ABBVIE INC. | $26.89 | 01/29/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1106126832 | CMS |
| Amgen Inc. | $15.17 | 09/17/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117687190 | CMS |
| Amgen Inc. | $16.89 | 10/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117687192 | CMS |
| Astellas Pharma US Inc | $14.89 | 05/22/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1139353043 | CMS |
| AstraZeneca Pharmaceuticals LP | $15.35 | 09/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104350750 | CMS |
| AstraZeneca Pharmaceuticals LP | $13.49 | 11/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104735425 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $18.71 | 08/28/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1118103427 | CMS |
| Esperion Therapeutics, Inc. | $16.35 | 11/13/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1129456098 | CMS |
| Lilly USA, LLC | $14.18 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135360994 | CMS |
| Lilly USA, LLC | $22.38 | 03/05/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135372904 | CMS |
| Lilly USA, LLC | $20.08 | 07/15/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135384091 | CMS |
| Lilly USA, LLC | $21.13 | 08/19/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1135396783 | CMS |
| Novo Nordisk Inc | $18.96 | 07/30/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096586585 | CMS |
| Novo Nordisk Inc | $18.21 | 10/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096894195 | CMS |
| PFIZER INC. | $27.11 | 04/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131230700 | CMS |
| PFIZER INC. | $21.44 | 07/23/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131772963 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.